Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Children with Brain Tumors: Review of Single Center Experience

Ki Woong Sung, M.D., Ph.D.,1 Do Hoon Lim, M.D., Ph.D.,2 Hyung Jin Shin, M.D., Ph.D.3
Departments of Pediatrics,1 Radiation Oncology,2 Neurosurgery,3 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

The prognosis of brain tumors in children has improved for last a few decades. However, the prognosis remains dismal in patients with recurrent brain tumors. The outcome for infants and young children in whom the use of radiotherapy (RT) is very limited because of unacceptable long-term adverse effect of RT remains poor. The prognosis is also not satisfactory when a large residual tumor remains after surgery or when leptomeningeal seeding is present at diagnosis. In this context, a strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) has been explored to improve the prognosis of recurrent or high-risk brain tumors. This strategy is based on the hypothesis that chemotherapy dose escalation might result in improvement in survival rates. Recently, the efficacy of tandem HDCT/auto-SCT has been evaluated in further improving the outcome. This strategy is based on the hypothesis that further dose escalation might result in further improvement in survival rates. At present, the number of studies employing tandem HDCT/auto-SCT for brain tumors is limited. However, results of these pilot studies suggest that tandem HDCT/auto-SCT may further improve the outcome. In this review, we will summarize our single center experience with tandem HDCT/auto-SCT for recurrent or high-risk brain tumors.

Key Words: Brain neoplasms · Child · High-dose chemotherapy · Autologous stem cell transplantation.

INTRODUCTION

The prognosis of brain tumors in children has improved for the last 2–3 decades. However, the prognosis remains dismal in patients with relapsed brain tumors3,18. The outcome for infants and young children in whom the use of radiotherapy (RT) is very limited because of unacceptable long-term adverse effect of RT remains poor5,6,20. The prognosis is also not satisfactory when a large residual tumor remains after surgery or when leptomeningeal seeding is present at diagnosis13,29,30. The prognosis of high-grade gliomas (HGGs) remains very poor8,9,23. In addition, late adverse effects from RT, particularly craniospinal RT, is unavoidable5,20.

A strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) has been explored to improve the prognosis of patients with high-risk solid tumors2,17. This strategy is based on the hypothesis that dose escalation might improve the survival of children. The results of
randomized trials comparing HDCT/auto-SCT with chemotherapy alone in patients with high-risk neuroblastoma showed a better event-free survival (EFS) in the HDCT/auto-SCT arm than in the continuous chemotherapy arm. Thus, HDCT/auto-SCT has been the standard consolidation treatment for high-risk neuroblastoma. Following the success in high-risk neuroblastoma, the efficacy of HDCT/auto-SCT has been explored to improve the prognosis of relapsed or high-risk brain tumors and/or to avoid or minimize RT.

Although the prognosis of relapsed or high-risk solid tumors has improved by using HDCT/auto-SCT, it remains still unsatisfactory. The main cause of failure after single HDCT/auto-SCT is relapse or tumor progression rather than treatment-related mortality (TRM). Thus, some investigators have explored the efficacy of tandem HDCT/auto-SCT to further improve the outcome. This strategy is based on the hypothesis that further dose escalation might result in further improvement in survival rates. Results from a small number of pilot studies suggest that further dose escalation might result in further improvements in the EFS. Our center has used tandem HDCT/auto-SCT since 2005 for the treatment of relapsed or high-risk brain tumors in children and adolescents. Here, we briefly review our experience with tandem HDCT/auto-SCT for brain tumors (Table 1).

**HDCT/AUTO-SCT FOR RELAPSED BRAIN TUMORS IN CHILDREN AND ADOLESCENTS**

**Relapsed medulloblastoma: KSPNO S-053 study**

The outcome of relapsed medulloblastoma (MB) remains dismal with conventional treatment modalities. Thus, the Korean Society of Pediatric Neuro-Oncology (KSPNO) investigated the efficacy and toxicity of HDCT/auto-SCT for improving the outcomes of patients with relapsed MB. A total of 15 patients with relapsed MB were enrolled in the KSPNO S-053 study from 2005 to 2007. All patients received approximately four cycles of salvage chemotherapy after relapse. Thirteen underwent HDCT/auto-SCT; carboplatin+thiotepa+etoposide (CTE) and cyclophosphamide+melphalan (CyM) regimens were used for the first HDCT and second HDCT, respectively, and seven underwent second HDCT. One TRM due to hepatic veno-occlusive disease (VOD) occurred during first HDCT but second HDCT was tolerable with no further TRM. The 3-year overall survival (OS) and event-free survival (EFS) rates (±95% confidence intervals) were 33.3±12.2% and 26.7±11.4%, respectively. When the analysis was confined to only patients who achieved a complete response (CR) or partial response (PR) prior to HDCT, the probability of 3-year OS rates was 40.0±15.5%. No patients with stable disease (SD) or progressive disease (PD) survived. This study showed that the tumor status before HDCT/auto-SCT had a crucial impact on the outcome after HDCT/auto-SCT. These results will provide additional evidence for a rational selection of patients for HDCT/auto-SCT after relapse/progression, considering significant risk and cost accompanying HDCT/auto-SCT.

**Relapsed germ cell tumors: KSPNO S-053 study**

The outcomes in patients with relapsed or progressed central nervous system (CNS) germ cell tumors (CNS-GCTs), especially those with non-germinomatous GCTs (NGGCTs), remain poor, and there is no clear consensus on management of these tumors. In this context, the KSPNO conducted a prospective, multicenter clinical study to evaluate the feasibility and effectiveness of tandem HDCT/auto-SCT in treating children with relapsed or progressed CNS-GCTs. Eleven patients with NGGCTs and nine patients with germinomas were enrolled. Patients received between two and eight cycles of conventional chemotherapy prior to HDCT/auto-SCT with or without RT. Overall, 16 patients proceeded to the first HDCT/auto-SCT, and nine proceeded to the second HDCT/auto-SCT. CTE and CyM regimens were used for the first and second HDCT, respectively. Toxicities during HDCT/auto-SCT were acceptable, and there was no TRM. Twelve patients experienced relapse or progression again; however, four patients with germinomas remain alive after subsequent RT. Therefore, a total of 12 patients (four NGGCTs and eight germinomas) remain alive with a median follow-up of 47 months after initial relapse or progression. The probability of 3-year OS was 59.1±11.2% (36.4±14.5% for NGGCTs vs. 88.9±10.5% for germinomas, P=0.028). RT, particularly craniospinal RT, was associated with a better tumor response prior to HDCT/auto-SCT and a better final outcome. This study showed that tandem HDCT/auto-SCT is a feasible approach in the treatment of relapsed or progressed CNS-GCTs. Further studies with larger cohorts of patients are needed to elucidate the possible role of HDCT/auto-SCT in the treatment of relapsed or progressed CNS-GCTs.
### Table 1. Summary of clinical trials using tandem HDCT/auto-SCT

<table>
<thead>
<tr>
<th>Study</th>
<th>Eligibility</th>
<th>No. of patients</th>
<th>Pre-HDCT treatment</th>
<th>HDCT regimen</th>
<th>Outcome</th>
<th>TRM during HDCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Park et al.</td>
<td>Recurrent MB (KSPNO)</td>
<td>15 MBs</td>
<td>4 cycles of chemotherapy (VICE) Surgery if possible RT if possible</td>
<td>HDCT1 : CTE (n=13) HDCT2 : CyM (n=7)</td>
<td>3-year OS 33.3±12.2% 3-year EFS 26.7±1.4%</td>
<td>1 of 13 HDCT1 (7.7%) 0 of 7 HDCT2 (0%)</td>
</tr>
<tr>
<td>Baek et al.</td>
<td>Recurrent GCT (KSPNO)</td>
<td>9 germinomas 11 NGGCTs</td>
<td>2–8 cycles of chemotherapy (variable regimens) Surgery if possible RT if possible</td>
<td>HDCT1 : CTE (n=16) HDCT2 : CyM (n=9)</td>
<td>3-year OS (all patients) 59.1±11.2% 3-year OS (germinoma) 88.9±10.5% 3-year EFS (all patients) 38.6±11.2% 3-year EFS (germinoma) 37.0±18.7%</td>
<td>0 of 16 HDCT1 (0%) 0 of 9 HDCT2 (0%)</td>
</tr>
<tr>
<td>Sung et al.</td>
<td>Malignant brain tumors in children &lt;3 years of age (single center)</td>
<td>25 (8 MBs, 3 PNETs, 5 ATRTs, 6 AEs, 2 GMs, 1 MFH)</td>
<td>6 cycles of chemotherapy (A-B-A-B-A-B)</td>
<td>HDCT1 : CTE (n=21) HDCT2 : CyM (n=20)</td>
<td>3-year OS 67.8±9.4% 3-year EFS 55.5±10.0%</td>
<td>1 of 21 HDCT1 (4.8%) 1 of 20 HDCT2 (5.0%)</td>
</tr>
<tr>
<td>Sung et al.</td>
<td>High-risk MB (single center)</td>
<td>17 M+ MBs 3 R+ M0 MBs</td>
<td>6 cycles of chemotherapy (A-B-A-B-A-B)</td>
<td>HDCT1 : CTE (n=20) HDCT2 : CyM (n=20)</td>
<td>5-year OS 73.9±10.2% 5-year EFS 70.0±13.0%</td>
<td>0 of 20 HDCT1 (0%) 2 of 20 HDCT2 (10.0%)</td>
</tr>
<tr>
<td>Sung et al.</td>
<td>ATRT (single center)</td>
<td>5 pts &lt;3 years of age 8 pts &gt;3 years of age</td>
<td>6 cycles of chemotherapy (A-B-A-B-A-B)</td>
<td>HDCT1 : CTE (n=10) HDCT2 : CyM (n=8)</td>
<td>5-year OS 34.6±14.4% 5-year EFS 38.5±13.5%</td>
<td>No patients &lt;3 years of age survived</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>High-grade gliomas (single center)</td>
<td>30 (16 GMs, 7 AAs, 7 others)</td>
<td>Variable chemotherapy Surgery, local RT</td>
<td>HDCT1 : CTE (n=13) HDCT2 : CyM (n=11)</td>
<td>3-year OS 31.5±9.2% 3-year EFS 23.7±8.2%</td>
<td>0 of 13 HDCT1 (0%) 1 of 11 HDCT2 (9.1%)</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>Anaplastic ependymoma (in press; single center)</td>
<td>8 pts &lt;3 years of age 6 pts &gt;3 years of age</td>
<td>6 cycles of chemotherapy (A-B-A-B-A-B)</td>
<td>HDCT1 : CTE (n=14) HDCT2 : CyM (n=13)</td>
<td>5-year OS 85.1±9.7% 5-year EFS 50.0±13.4%</td>
<td>0 of 14 HDCT1 (0%) 1 of 13 HDCT2 (7.7%)</td>
</tr>
</tbody>
</table>

**HDCT/auto-SCT**: high-dose chemotherapy and autologous stem cell transplantation, **TRM**: treatment-related mortality, **KSPNO**: Korean Society of Pediatric Neuro-Oncology, **MB**: medulloblastoma, **VICE**: vincristine+ifosfamide+carboplatin+etoposide, **RT**: radiotherapy, **HDCT1**: first HDCT, **CTE**: carboplatin+tiotepa+etoposide, **HDCT2**: second HDCT, **CyM**: cyclophosphamide+melphalan, **OS**: overall survival, **EFS**: event-free survival, **GCT**: germ cell tumor, **NGGCT**: non-germinomatous GCT, **PNET**: primitive neuroectodermal tumor, **ATRT**: atypical teratoid/rhabdoid tumor, **AE**: anaplastic ependymoma, **GM**: glioblastoma multiforme, **MFH**: malignant fibrous histiocytoma, **CECV**: cisplatin+etoposide+cyclophosphamide+vincristine, **CSRT**: craniospinal radiotherapy, **AA**: anaplastic astrocytoma
HDCT/auto-SCT for brain tumors in very young children: single center experience

Treatment of malignant brain tumors in young children is challenging because RT is used minimally due to the risk of functional impairment of the developing brain, and late adverse effects, including global reduction in the intelligence quotient, cognitive deficits, and neuroendocrine dysfunction. In an effort to minimize these effects, a number of institutions and national groups have adopted chemotherapy-based strategies designed to avoid or delay RT, though outcomes have been largely unsatisfactory. Clinical trials using HDCT/auto-SCT for treatment of infants and young children with malignant brain tumors have shown that it is possible to avoid or defer RT until 3 years of age while maintaining or improving survival rates.

For this reason, we prospectively evaluated the feasibility and effectiveness of tandem HDCT/auto-SCT in children under 3 years of age with malignant brain tumors. This treatment strategy aimed to simultaneously improve survival and reduce the risk of significant late adverse effects of RT. A total of 25 children under 3 years of age received tandem HDCT/auto-SCT following six cycles of induction chemotherapy. RT was either not given or deferred until 3 years of age if the patient achieved CR after tandem HDCT/auto-SCT. Local RT was given only if gross residual tumor (>1.5 cm²) remained after surgery, and craniospinal RT was given only if leptomeningeal seeding was present at the time of diagnosis. Tumors relapsed or progressed in nine patients (five during induction treatment), and two of these patients survived after receiving salvage treatment, including RT. Two patients died due to toxicities during tandem HDCT/auto-SCT. A total of 16 patients survived to a median follow-up period of 52 months from the time of diagnosis. Four of these patients did not receive RT, two received local RT alone, three received craniospinal RT alone and seven received both. The 5-year OS and EFS rates were 67.8±9.4% and 55.5±10.0%, respectively. Neuroendocrine and neurocognitive functions evaluated at 3 years after tandem HDCT/auto-SCT were acceptable. The results of this study indicate that tandem HDCT/auto-SCT may improve survival in young children with malignant brain tumors with an acceptable level of risk of long-term toxicity.

HDCT/AUTO-SCT FOR HIGH-RISK EMBRYONAL TUMORS

High-risk MB: single center experience

MB is the most common malignant brain tumor in children, accounting for 20% of childhood brain tumors. The standard treatment of MB consists of surgery; RT, including craniospinal RT; and chemotherapy. The conventional doses of RT have been around 36 Gy to the craniospinal axis combined with a boost of 18–20 Gy to the posterior fossa, for a total dose of 54–56 Gy. Children who survive MB are at risk for various late adverse effects primarily attributable to RT, particularly craniospinal RT. The prognosis for high-risk MB (defined by metastasis and/or postoperative residual tumor >1.5 cm³) is unsatisfactory, despite standard-dose craniospinal RT; 5-year survival is <55%.

HDCT/auto-SCT has been used to treat high-risk or recurrent MBs. Some investigators have applied this treatment modality in relapsed/progressed cases, and some reports exist that use this strategy as a first-line treatment for newly diagnosed MBs. Gajjar and colleagues have reported the results of a prospective study (St. Jude MB 96 study) using tandem HDCT/auto-SCT in patients with high-risk MB. In their study, patients received 36.0–39.6 Gy of craniospinal RT followed by four cycles of HDCT/auto-SCT, and the 5-year EFS rate was 70%. The EFS rate was encouraging; however, late adverse effects from dose-intense chemotherapy might potentiate late adverse effects from conventional RT.

For this reason, we assessed the feasibility and effectiveness of reduced-dose craniospinal RT followed by tandem HDCT/auto-SCT in reducing late adverse effects without jeopardizing survival among children with high-risk MB. From 2005 through 2010, twenty consecutive children aged >3 years with high-risk MB were assigned to receive two cycles of pre-RT chemotherapy, reduced craniospinal RT (23.4 or 30.6 Gy) combined with local RT to the primary site (total 54.0 Gy), and four cycles of post-RT chemotherapy followed by tandem HDCT/auto-SCT. CTE and CyM regimens were used for the first and second HDCT, respectively. Of 20 patients with high-risk MB, 17 had metastatic disease and three had a postoperative residual tumor >1.5 cm³ without metastasis. The tumor relapsed/progressed in four patients, and two patients died from toxicities during the second HDCT/auto-SCT. Therefore, 14 patients remained event-free at a median follow-up of 46 months from di-
agnosis. The probability of 5-year EFS was 70.0±10.3% for all patients and 70.6±11.1% for patients with metastases. Late adverse effects evaluated at a median of 36 months after tandem HDCT/auto-SCT were acceptable. This study suggests that, in children with high-risk MB, the dose of craniospinal RT might be reduced without jeopardizing survival by using tandem HDCT/auto-SCT.

Atypical teratoid/rhabdoid tumors : single center experience

CNS atypical teratoid/rhabdoid tumors (ATRTs) are highly malignant and are associated with significantly worse OS than other embryonal tumors. The very poor prognosis of ATRT in young children may be related to the limited use of RT because of the risks of functional impairment of the developing brain and late adverse effects. Multiple chemotherapeutic approaches have been attempted to defer RT; however, OS remains dismal. For older children, a few studies have suggested that outcome might be improved with standard-dose craniospinal RT and high-dose alkylator-based chemotherapy. However, various late adverse effects primarily attributable to RT, particularly craniospinal RT, were unavoidable.

For this reason, we prospectively evaluated the effectiveness of tandem HDCT/auto-SCT in improving the survival of patients with ATRT while reducing the risks of late adverse effects from RT. For young children (<3 years old), tandem HDCT/auto-SCT was administered after six cycles of induction chemotherapy. RT was deferred until after 3 years of age unless the tumor showed relapse or progression. For older children, a few studies have suggested that outcome might be improved with standard-dose craniospinal RT and high-dose alkylator-based chemotherapy. However, various late adverse effects primarily attributable to RT, particularly craniospinal RT, were unavoidable.

For this reason, we reported our experience with HDCT/auto-SCT for HGGs in 30 children and adolescents (16 glioblastomas, seven anaplastic astrocytomas, and seven other HGGs) between 2006 and 2015. Gross or near total resection was possible in 11 patients. Front-line treatment after surgery was RT in 14 patients and chemotherapy in the remaining 16 patients including three patients less than 3 years old. Eight of 12 patients who remained progression free and five of the remaining 18 patients who experienced progression during induction treatment underwent the first HDCT/auto-SCT with CTE regimen and 11 of them proceeded to the second HDCT/auto-SCT with CyM regimen. One patient died from hepatic VOD during the second HDCT/auto-SCT; otherwise, toxicities were manageable. Four patients in CR and three of seven patients in PR or second PR at the first HDCT/auto-SCT remained event free however, two with progressive tumor experienced progression again. The probability of 3-year OS after the first HDCT/
auto-SCT in 11 patients in CR, PR, or second PR was 58.2±16.9%. Tumor status at the first HDCT/auto-SCT was the only significant factor for outcome after HDCT/auto-SCT. This study suggests that the outcome of HGGs in children and adolescents after HDCT/auto-SCT is encouraging if the patient could achieve CR or PR before HDCT/auto-SCT.

Anaplastic ependymoma: single center experience (in press)

Ependymomas occur more frequently in children than in adults. Ependymomas have been classified as WHO grades I, II, and III based on the histologic findings and surgical resection with or without adjuvant RT has been the mainstay therapy. The effectiveness of chemotherapy is controversial; however, some studies have suggested that chemotherapy may be beneficial for ependymomas that are not completely resected, making it possible to either delay RT without compromising survival or facilitate resection of residual tumors. The potential beneficial effects of chemotherapy are expected to be more prominent in high-grade ependymomas with anaplastic features than in low-grade ependymomas. The results of our early study involving five very young children with anaplastic ependymomas have also suggested that tandem HDCT/auto-SCT is a feasible therapeutic option that exhibits acceptable toxicities and may improve the survival of patients.\(^\text{26}\)

Recently, we have evaluated the results of multimodal treatment that includes tandem HDCT/auto-SCT, not only in this young population, but also in older children with anaplastic ependymomas, and with longer durations of follow-up. Fourteen patients with anaplastic ependymomas diagnosed from 2006 to 2014 were reviewed. Six cycles of induction chemotherapy were administered to all patients before they underwent tandem HDCT/auto-SCT. Patients who were older than 3 years of age received RT after two cycles of induction chemotherapy. In patients under 3 years of age, RT was either omitted or delayed until they reached 3 years of age, if the patients experienced CR after tandem HDCT/auto-SCT. All patients, including two who experienced disease progression during induction treatment, underwent the first HDCT/auto-SCT, and 13 subsequently underwent the second HDCT/auto-SCT. One patient died from hepatic VOD during the second HDCT/auto-SCT; other toxicities occurring during tandem HDCT/auto-SCT were manageable. Relapses or progression occurred in seven patients, and five of them remain alive after salvage treatment, including surgery and RT. The 5-year OS and EFS rates were 85.1±9.7% and 50.0±13.4%, respectively. The results of this study suggest that multimodal treatment including tandem HDCT/auto-SCT could be a feasible option for improving survival in children with anaplastic ependymomas.

**Toxicities of tandem HDCT/auto-SCT: single center experience**\(^\text{15}\)

Recently, the number of studies examining the efficacy of tandem HDCT/auto-SCT to further improve the outcome of high-risk or recurrent brain tumors is increasing. However, tandem HDCT/auto-SCT might be associated with greater toxicity and higher TRM rates than single HDCT/auto-SCT. However, studies addressing the toxicity associated with tandem HDCT/auto-SCT for brain tumors, particularly during the second HDCT/auto-SCT, are limited.

For this reason, we evaluated the toxicity of tandem HDCT/auto-SCT using the CTE and CyM regimens that we have used regularly since 2005. We also evaluated risk factors for morbidity and mortality during tandem HDCT/auto-SCT, particularly during the second HDCT/auto-SCT. A total of 109 patients who underwent the first HDCT/auto-SCT and 100 who proceeded to the second HDCT/auto-SCT between 2005 and 2013 were included. Hematologic recovery was rapid during both the first and second HDCT/auto-SCT. In the first HDCT/auto-SCT, mucositis-related gastrointestinal toxicity was frequent, and two (1.8%) patients died from toxicity (one from hepatic VOD and the other from sepsis). In the second HDCT/auto-SCT, mucositis-related toxicity was milder than in the first round. However, hepatic VOD frequency was high (20.0%), and six (6.0%) patients died from toxicity (four from hepatic VODs, one from asphyxia, and one from sepsis). Multivariate analysis indicated that age younger than 8 years was the only significant predictor for hepatic VOD. All six patients who died from toxicity during the second HDCT/auto-SCT were younger than 9 years of age. This study demonstrates that tandem HDCT/auto-SCT using CTE/CyM regimens was generally feasible. However, dose reduction during the second HDCT/auto-SCT in young children might be needed to decrease the death rate from toxicity.

**DISCUSSION**

Our experience with tandem HDCT/auto-SCT as salvage
treatment for relapsed brain tumors or as front-line treatment for high-risk tumors suggests that tandem HDCT/auto-SCT might improve survival outcomes or reduce RT dose without jeopardizing survival rates. However, there are a few significant limitations or clinical problems to be solved.

First, risk stratifications for inclusion criteria in our previous studies were based on the conventional clinical parameters (age, the presence of metastasis, significant postoperative residual tumor, or conventional histology). Recent efforts at stratifying brain tumors on the basis of their molecular features have subdivided brain tumors into various distinct molecular subgroups characterized by disparate transcriptional signatures, mutational spectra, copy number profiles, and clinical features. Molecular stratification of brain tumors with use of a gene expression–based approach will improve current risk stratification. In the next phase of clinical trial employing HDCT/auto-SCT, the selection of patients will be based also on these data, thus potentially avoiding intensive treatment regimen to some of those patients previously considered as high-risk. Second, the number of patients enrolled in our single arm pilot studies was low due to the rarity of each brain tumor. In addition, there is no study comparing the effectiveness and toxicity between single and tandem HDCT/auto-SCT in patients with brain tumors. Therefore, prospective randomized controlled studies with a larger cohort of patients are needed to confirm the results of our single arm pilot studies. Nation-wide trials might be necessary. Third, tandem HDCT/auto-SCT might be associated with greater toxicity and higher TRM rates than single HDCT/auto-SCT. Therefore, long-term follow-up is needed to evaluate whether the survival benefits from tandem HDCT/auto-SCT or benefits from RT dose reduction outweigh the long-term risks of tandem HDCT/auto-SCT. Fourth, we have used only CTE and CyM regimens for tandem HDCT/auto-SCT in order to overcome possible drug resistance and avoid overlapping toxicities. However, toxicities during the second HDCT/auto-SCT were significant and some patients died from toxicities, particularly hepatic VOD. Therefore, dose modification of current regimen or employment of other HDCT regimen might be considered to reduce toxicities during the second HDCT/auto-SCT. Fifth, our studies for relapsed brain tumors showed that the tumor status before HDCT/auto-SCT had a crucial impact on the survival after HDCT/auto-SCT. The significance of local control via surgery or RT has been previously suggested in several types of solid tumors. In our experience with relapsed brain tumors, debulking surgery and RT after relapse/progression were also prognostic factors, further highlighting the importance of local control. Thus, surgery (repeated if necessary) and RT must be performed whenever feasible in order to reduce the tumor burden as much as possible prior to HDCT/auto-SCT. In addition, new chemotherapeutic drug such as target agents or immune regulatory agents might be needed to improve the response before HDCT/auto-SCT.

CONCLUSION

In conclusion, the results of our single center pilot studies suggest that tandem HDCT/auto-SCT might improve survival outcomes or reduce RT dose without jeopardizing survival rates in patients with relapsed or high-risk brain tumor. Prospective randomized controlled studies with a larger cohort of patients are needed to confirm the results of our studies.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

INFORMED CONSENT

This type of study does not require informed consent.

References

27. Sung KW, Lim DH, Yi ES, Choi YB, Lee JW, Yoo KH, et al.: Tandem high-
